Creative Medical Technology Holdings Inc (CELZ)

[gint1]

CELZ.... "We are confident that once we have completed Phase I clinical trials to demonstrate human safety of this cell, we will be well positioned to allow access to end stage cancer patients under the Right to Try law," said Thomas Ichim, Ph.D

Thomas Ichim PhD
Dr. Ichim has 20 years experience in the biotechnology industry, having served as the Vice President of Cellular Therapies, Intrexon, Inc. Dr. Ichim is an accomplished inventor and was the President and Chief Scientific Officer at Medistem, Inc., a recently acquired publicly traded company. Dr. Ichim has a PhD in Immunology from University of Sciences Arts and Technology, Olveston Monserrat, a MSc in Microbiology and Immunology from University of Western Ontario, London, Ontario, Canada and a BSc in Biology from the University of Waterloo, Waterloo, Ontario, Canada. Dr. Ichim has written over 100 peer reviewed publications and has founded and operated successful biotech companies in the past.